Crucell Announces Large Scale Quinvaxem Vaccinations in Ethiopia
Quinvaxem(TM) has now been introduced in several Latin American and African countries vaccination programs supported and co-financed by supranational organizations.
"The multiple year contracts that the supranational organizations have granted to Crucell, underline Crucell's place as a leading supplier of such important vaccines. Quinvaxem(TM) is the first internationally available fully-liquid vaccine containing these five life saving antigens and it will make a significant contribution to children's vaccination programs in the developing world," said Crucell's President and CEO, Dr. Ronald H.P. Brus. "Quinvaxem(TM) will be an important contributor to the company's 2007 total revenues, being estimated in excess EURO 200 million and our objective to be cash neutral in 2007."
Quinvaxem(TM) was co-developed with Novartis and is produced in Crucell's laboratories in South Korea. Current demand for the vaccine exceeds 50 million doses. The total market potential is estimated to be 150 million doses per year in 3 to 4 years.
Organizations
Other news from the department research and development
These products might interest you
Whatman™ folded filter papers by Cytiva
Whatman folded filter papers
Convenient folded formats speed up your sample preparation
Systec H-Series by Systec
Safe, reproducible and validatable sterilization of liquids, solids and waste
Autoclaves with 65-1580 liters usable space, flexibly expandable for various applications
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.